Xeris Biopharma (XERS) Expected to Announce Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $57.61 million for the quarter.

Xeris Biopharma Stock Down 1.5 %

Shares of NASDAQ XERS opened at $4.64 on Tuesday. The stock’s fifty day simple moving average is $4.58 and its 200 day simple moving average is $3.81. The stock has a market capitalization of $725.63 million, a price-to-earnings ratio of -10.31 and a beta of 1.10. Xeris Biopharma has a 52-week low of $1.72 and a 52-week high of $6.07.

Wall Street Analyst Weigh In

XERS has been the topic of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. Finally, Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.10.

Insider Buying and Selling

In related news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.56% of the stock is currently owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.